Terms: = Bone cancer AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Diagnosis
43 results:
1. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
2. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract] [Full Text] [Related]
3. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
Gurnari C; Pascale MR; Vitale A; Diral E; Tomelleri A; Galossi E; Falconi G; Bruno A; Crisafulli F; Frassi M; Cattaneo C; Bertoli D; Bernardi M; Condorelli A; Morsia E; Poloni A; Crisà E; Caravelli D; Triggianese P; Brussino L; Battipaglia G; Bindoli S; Sfriso P; Caroni F; Dragani M; Mallegni F; Pilo F; Firinu D; Curti A; Papayannidis C; Olivieri A; Kordasti S; Albano F; Pane F; Musto P; Bocchia M; Lugli E; Breccia M; Frigeni M; Dagna L; Greco R; Franceschini F; Campochiaro C; Cantarini L; Voso MT
Am J Hematol; 2024 Feb; 99(2):254-262. PubMed ID: 38108611
[TBL] [Abstract] [Full Text] [Related]
4. Identification of Cell Type-Specific Effects of
Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
[TBL] [Abstract] [Full Text] [Related]
5. Hypoplastic form of myelodysplastic neoplasm.
Votavová H; Lenertová Z; Votava T; Beličková M
Klin Onkol; 2023; 36(3):206-214. PubMed ID: 37353349
[TBL] [Abstract] [Full Text] [Related]
6. Distinct power of bone marrow microRNA signatures and tumor suppressor genes for early detection of acute leukemia.
Memari F; Tavakolpour V; Mohajeri N; Poopak B; Fallah P; Alizadeh E; Kouhkan F; Zarghami N
Clin Transl Oncol; 2022 Jul; 24(7):1372-1380. PubMed ID: 35247197
[TBL] [Abstract] [Full Text] [Related]
7. Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation.
Soerensen JF; Aggerholm A; Rosenberg CA; Bill M; Kerndrup GB; Ebbesen LH; Hansen MH; Roug AS; Ludvigsen M
Bone Marrow Transplant; 2022 Mar; 57(3):460-465. PubMed ID: 35027675
[TBL] [Abstract] [Full Text] [Related]
8. The Application of NextGen Sequencing in the diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract] [Full Text] [Related]
9. Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2022 Mar; 97(3):352-372. PubMed ID: 34985762
[TBL] [Abstract] [Full Text] [Related]
10. ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
West RR; Calvo KR; Embree LJ; Wang W; Tuschong LM; Bauer TR; Tillo D; Lack J; Droll S; Hsu AP; Holland SM; Hickstein DD
Blood Adv; 2022 Feb; 6(3):793-807. PubMed ID: 34529785
[TBL] [Abstract] [Full Text] [Related]
11. Case report: Rare myeloid sarcoma development following renal transplantation with KRAS and dnmt3a gene mutations.
Wu D; Lu X; Yan X; Gao R
Diagn Pathol; 2021 Aug; 16(1):82. PubMed ID: 34465355
[TBL] [Abstract] [Full Text] [Related]
12. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G; Kim T; Novitzky-Basso I; Kim KH; Smith A; Stockley T; Capochichi JM; Al-Shaibani Z; Pasic I; Law A; Lam W; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Schimmer A; McNamara C; Murphy T; Maze D; Gupta V; Sibai H; Chan S; Yee K; Minden M; Zhang Z; Schuh A; Kim DDH
Bone Marrow Transplant; 2021 Aug; 56(8):1908-1918. PubMed ID: 33767401
[TBL] [Abstract] [Full Text] [Related]
14. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
[TBL] [Abstract] [Full Text] [Related]
16. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
[TBL] [Abstract] [Full Text] [Related]
17. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
Hong M; Zhu H; Sun Q; Zhu Y; Miao Y; Yang H; Qiu HR; Li JY; Qian SX
Aging (Albany NY); 2020 Apr; 12(7):5792-5811. PubMed ID: 32238611
[TBL] [Abstract] [Full Text] [Related]
18. Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2020 Jan; 95(1):97-115. PubMed ID: 31736132
[TBL] [Abstract] [Full Text] [Related]
19. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
Yun S; Sharma R; Chan O; Vincelette ND; Sallman DA; Sweet K; Padron E; Komrokji R; Lancet JE; Abraham I; Moscinski LC; Cleveland JL; List AF; Zhang L
Leuk Res; 2019 Sep; 84():106194. PubMed ID: 31357093
[TBL] [Abstract] [Full Text] [Related]
[Next]
